Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

被引：5
|
作者：
Concin, Nicole
Braicu, Ioana
Combe, Pierre
Ray-Coquard, Isabelle Laure
Joly, Florence
Harter, Philipp
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5567
引用
收藏
页数：2
相关论文
共 20 条
  • [1] Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Ray-Coquard, Isabelle
    Braicu, Ioana
    Berger, Regina
    Mahner, Sven
    Sehouli, Jalid
    Zeimet, Alain G.
    lauraine, Eric Pujade
    Cassier, Philippe Alexandre
    Moll, Utemartha
    Ulmer, Hanno
    Leunen, Karin
    Marth, Christian
    Vergote, Ignace
    Concin, Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Concin, Nicole
    Braicu, Loana
    Berger, Regina
    Mahner, Sven
    Sehouli, Jalid
    Zeimet, Alain G.
    Pujade-Lauraine, Eric
    Cassier, Philippe Alexandre
    Moll, Ute Martha
    Ulmer, Hanno
    Leunen, Karin
    Marth, Christian
    Vergote, Ignace
    Ray-Coquard, Isabelle Laure
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium
    Ray-Coquard, Isabelle
    Braicu, Ioana
    Berger, Regina
    Mahner, Sven
    Sehouli, Jalid
    Pujade-Lauraine, Eric
    Cassier, Philippe Alexandre
    Moll, Ute Martha
    Ulmer, Hanno
    Leunen, Karin
    Zeimet, Alain Gustave
    Marth, Christian
    Vergote, Ignace
    Concin, Nicole
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [4] Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
    Alqaisi, Husam A.
    Cohn, David E.
    Chern, Jing-Yi
    Duska, Linda R.
    Jewell, Andrea
    Corr, Bradley R.
    Winer, Ira Seth
    Girda, Eugenia
    Crispens, Marta A.
    Dhani, Neesha C.
    Madariaga, Ainhoa
    Grant, Robert C.
    Malaguti, Matthew
    Lee, Crystal
    Bowering, Valerie
    Wong, Horace
    Poothullil, Andrew
    Speers, Vanessa
    Wang, Lisa
    Bedard, Philippe L.
    Brady, John C.
    Nixon, Andrew B.
    Chen, Li
    O'Connor, Claire
    Zamboni, William
    Mckee, Tawyna
    Moscow, Jeffrey A.
    Oza, Amit M.
    Lheureux, Stephanie
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 993 - 1001
  • [5] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [6] Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
    Colombo, Nicoletta
    Tomao, Federica
    Panici, Pierluigi Benedetti
    Nicoletto, Maria Ornella
    Tognon, Germana
    Bologna, Alessandra
    Lissoni, Andrea Alberto
    DeCensi, Andrea
    Lapresa, Mariateresa
    Mancari, Rosanna
    Palaia, Innocenza
    Tasca, Giulia
    Tettamanzi, Francesca
    Alvisi, Maria Francesca
    Rulli, Eliana
    Poli, Davide
    Carlucci, Luciano
    Torri, Valter
    Fossati, Roldano
    Biagioli, Elena
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 505 - 513
  • [7] Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial
    Banerjee, Susana
    Giannone, Gaia
    Clamp, Andrew R.
    Ennis, Darren P.
    Glasspool, Rosalind M.
    Herbertson, Rebecca
    Krell, Jonathan
    Riisnaes, Ruth
    Mirza, Hasan B.
    Cheng, Zhao
    McDermott, Jacqueline
    Green, Clare
    Kristeleit, Rebecca S.
    George, Angela
    Gourley, Charlie
    Lewsley, Liz-Anne
    Rai, Debbie
    Banerji, Udai
    Hinsley, Samantha
    McNeish, Iain A.
    JAMA ONCOLOGY, 2023, 9 (05) : 675 - 682
  • [8] ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator's choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.
    Olawaiye, Alexander
    Monk, Bradley J.
    Herzog, Thomas J.
    Copeland, Larry J.
    Coleman, Robert L.
    Moore, Kathleen N.
    Randall, Leslie M.
    Slomovitz, Brian M.
    O'Malley, David M.
    Eskander, Ramez Nassef
    Pothuri, Bhavana
    Van Gorp, Toon
    Pignata, Sandro
    Nicum, Shibani
    Tudor, Iulia Cristina
    Nguyen, Dorothy D.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
    Lee, Elizabeth K.
    Tan-Wasielewski, Zhenying
    Aghajanian, Carol
    Coleman, Robert L.
    Curtis, Jennifer
    Hirsch, Michelle S.
    Matulonis, Ursula A.
    Cantley, Lewis C.
    Mills, Gordon B.
    Doyle, L. Austin
    Liu, Joyce F.
    GYNECOLOGIC ONCOLOGY REPORTS, 2020, 32
  • [10] A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018
    Damian, Fernanda Bronzon
    De Melo, Andreia Cristina
    Dal Molin, Graziela Zibetti
    Rodrigues, Angelica Nogueira
    de Carvalho Calabrich, Aknar Freire
    Werutsky, Gustavo
    Abdo Filho, Elias
    Rebelatto, Taiane Francieli
    de Jesus, Rafaela Gomes
    Jimenez, Mirela Foresti
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12